PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005

被引：0
|
作者：
Riely, Gregory J. [1 ]
Kim, Dong-Wan [2 ]
Crino, Lucio [3 ]
Janne, Pasi A. [4 ]
Blackhall, Fiona H. [5 ]
Camidge, David R. [6 ]
Hirsh, Vera [7 ]
Mok, Tony S. K. [8 ]
Solomon, Ben [9 ]
Soria, Jean-Charles
Park, Keunchil [10 ]
Gadgeel, Shirish M. [11 ]
Martins, Renato G. [12 ]
Han, Ji-Youn
De Pas, Tommaso [13 ]
Bottomley, Andrew
Polli, Anna
Petersen, Jennifer A. [14 ]
Tassell, Vanessa R. [15 ]
Shaw, Alice T. [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Azienda Osped Perugia, Div Med, Perugia, Italy
[4] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Colorado Denver, Aurora, CO 80045 USA
[7] McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 2T5, Canada
[8] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[9] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia
[10] Sungkyunkwan Univ, Sch Med, Dept Med, Div Hem Onc, Seoul, South Korea
[11] Ayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[12] Univ Washington, Seattle, WA 98195 USA
[13] European Inst Oncol, Thorac Oncol Unit, Milan, Italy
[14] Pfizer Oncol, Hlth Econ & Global Outcomes Res, New York, NY USA
[15] Pfizer Oncol, Clin Res & Dev, New York, NY USA
[16] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Crizotinib; PF-02341066; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S411 / S412
页数：2
相关论文
共 50 条
  • [41] INCORPORATING CRIZOTINIB INTO CLINICAL PRACTICE AS A NEW STANDARD OF CARE (SOC) IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Soria, J.
    Blackhall, F.
    Solomon, B.
    Crino, L.
    Scagliotti, G.
    Bartlett, C. Huang
    Wilner, K.
    Ou, S. I.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S64 - S65
  • [42] Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer
    Ou, Sai-Hong Ignatius
    Bazhenova, Lyudmila
    Camidge, D. Ross
    Solomon, Benjamin J.
    Herman, June
    Kain, Tatiana
    Bang, Yung-Jue
    Kwak, Eunice L.
    Shaw, Alice T.
    Salgia, Ravi
    Maki, Robert G.
    Clark, Jeffrey W.
    Wilner, Keith D.
    Iafrate, A. John
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : 2044 - 2046
  • [43] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [44] Preliminary Characterization of Visual Events Reported by Patients (Pts) Receiving Crizotinib for the Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    Solomon, B.
    Chiappori, A.
    Lamb, A.
    Gawlicki, M. G.
    Kim, D. W.
    Park, K.
    Salgia, R.
    Wilner, K.
    Reisman, A.
    Petersen, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S231 - S231
  • [45] IMPACT OF CRIZOTINIB TREATMENT ON PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (QOL) IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Blackhall, F. H.
    Evans, T. L.
    Han, J.
    Salgia, R.
    Moro-Sibilot, D.
    Gettinger, S.
    Crino, L.
    Wilner, K.
    Reisman, A.
    Iyer, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 403 - 403
  • [46] Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)
    Crino, L.
    Ahn, M-J.
    Han, J-Y.
    Liu, X.
    Ou, S-H. I.
    Shaw, A. T.
    Yang, P-C.
    Shi, Y-K.
    Lanzalone, S.
    Polli, A.
    Wilner, K. D.
    Kim, D-W.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [47] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [48] Regarding the prognostic factors in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Hu, Limei
    Xie, Youjun
    Zhao, Hongying
    [J]. PULMONOLOGY, 2024, 30 (04): : 406 - 407
  • [49] Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer
    Zhang, Y.
    Liang, Z.
    Li, Y.
    Yang, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1003 - S1003
  • [50] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    [J]. DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
12345